CHO-Cell Technology & Engineering

Cute hamster in a futuristic environment

Chinese Hamster Ovary cells are the gold standard for production of biologicals. However, CHOs can be very challenging to optimize – we can help you with our deep understanding and many years of experience!


CHO-cells produce proteins with characteristics very similar to those in humans and thus are commonly used for production of therapeutics. Despite large improvements, however, the development and optimization of CHO-cell lines is often difficult and time-consuming.


acib has been involved in CHO cell genomic research from the beginning, including generation of a reference genome within an International consortium ( Using transcript-tomics, proteomics, metabolomics and noncoding RNA-omics, acib can characterize newly generated subclones or cell lines under different process conditions. This information is used to streamline CLD or optimise processes, supported by computational predictions using a genome-scale metabolic model. We also offer tools for targeted engineering approaches, e.g. CRISPR/Cas9 based targeted integration into predicted hot spots or modulation of gene expression levels by epigenetic engineering. Combined, acib’s expertise provides industrial partners with a deeper understanding of the limitations of their specific system with respect to productivity, growth and product quality, while also providing strategies to overcome these, to achieve reduced time to market and lower production costs.

Project Offer

Under protection of a CDA/NDA we provide detailed characterisation of your cell line and strategies for generating a tailored CHO-cell line or expression of your gene of interest. We can provide just a concept (2-3 month) or the wet-lab proof-of-concept (3-12 months). Any IP developed would fully belong to the investor/industrial partner.


Prof. Dr. Nicole Borth, Dr. Martina Baumann

Available for:

Investments, Joint Research Projects, Contract Research

Status of the project proposal:

Readiness Level 1-5


Will be generated for our industrial partner / investor


CHO-Cells, Therapeutic Proteins, Production Cell Line, Reference Genome, Epigenetics, Metabolic Model, Cell Engineering, Reliability, Stability, Productivity

Picture credits: Pixabay

Dr. Martin U. Trinker
Director Business Development & Fundraising
Krenngasse 37
8010 Graz
+43 316 873 9316